secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-028323
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports Q4 net loss $74.8M, cash $1.1B; pivotal data on track for 2025
-------------------------------------------------------------------------------

- Net loss $74.8M (Q4 2024) and $260.8M (FY 2024); cash & equivalents $1.1B, expected to fund into 2028.
- Pivotal data for zidesamtinib in TKI pre-treated ROS1+ NSCLC expected H1 2025; NDA submission mid-2025.
- Pivotal data for neladalkib in TKI pre-treated ALK+ NSCLC expected year-end 2025; Phase 3 ALKAZAR initiating H1 2025.
- Global Expanded Access Programs launched for zidesamtinib and neladalkib for eligible patients.
- Appointed Grant Bogle, former Epizyme CEO, to Board of Directors in December 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017025028323/0000950170-25-028323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017025028323/nuvl-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-028323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer